跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 51,580 条关于
“NTRK fusion-positive solid tumors”
全部
51,580
临床试验
35,894
药物
1,124
机构
163
资讯
14,399
3个月前
Vcare PharmaTech's Next-Generation TRK Inhibitor Eratrectinib Wins NMPA Approval for NTRK Fusion-Positive Solid Tumors
9个月前
InnoCare's Next-Generation TRK Inhibitor Zurletrectinib Receives NMPA Approval in China for NTRK Fusion-Positive Solid Tumors
7个月前
Repotrectinib Demonstrates Durable Activity in NTRK Fusion-Positive Solid Tumors with Promising Outcomes in TKI-Pretreated Patients
10个月前
InnoCare's Zurletrectinib Shows 90% Response Rate in Pediatric NTRK-Fusion Solid Tumors
去年
Next-Generation TRK Inhibitors Show Promise in Treating NTRK Fusion-Positive Cancers
去年
Repotrectinib Recommended for EU Approval in ROS1+ NSCLC and NTRK+ Solid Tumors
去年
CHMP Recommends Repotrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors in Europe
2个月前
ASCO Living Guideline Adds Repotrectinib and Zongertinib for Advanced NSCLC With Driver Alterations
去年
InnoCare Presents Promising Clinical Data for Multiple Oncology Pipeline Candidates at Major Medical Conferences
9个月前
Foundation Medicine Reaches Historic 100 Companion Diagnostic Approvals Milestone
第 1 页，共 1440 页
上一页
下一页
